Technology

ADVANCE Study

Prognomix goal is to determine genomic profile of T2D patients with renal, cardiac and vascular disease to develop pre-symptomatic, predictive markers facilitating prevention of complications using the ADVANCE cohort.

  • ADVANCE: is the largest clinical outcome trial in type 2 diabetics to date
  • 11,140 patients and samples for DNA with informed consent
  • Genetic sub-study led by P. Hamet and J. Tremblay
  • High acceptance for informed consent for the genetic studies worldwide
  • ADVANCE website

ADVANCE trial was performed in 20 countries indicated in red.

ADVANCE trial was performed in 20 countries indicated in red.